Top

Intensive Care Medicine

Published in:

01-08-2013 | Correspondence

Harm associated with 6 % tetrastarch 130 kDa [hydroxyethyl starch (HES) 130/0.4 and 130/0.42] is robust to sensitivity analysis by excluding Dolecek et al.

Authors: Amit Patel, Umeer Waheed, Stephen J. Brett

Published in: Intensive Care Medicine | Issue 8/2013

Excerpt

Dear Editor, …

Kranke P, Roewer N, Muellenbach RM (2013) “Colloid twice daily” is not fluid resuscitation! Inappropriate inclusion of clinical trials in meta-analyses may distract from gaps in evidence. Intensive Care Med. doi:10.1007/s00134-013-2954-4

Patel A, Waheed U, Brett S (2013) Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 39:811–822PubMedCrossRef

Dolecek M, Svoboda P, Kantorova I, Scheer P, Sas I, Bibrova J, Radvanova J, Radvan M (2009) Therapeutic influence of 20% albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial. Hepatogastroenterology 56:1622–1628PubMed

Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688PubMedCrossRef

Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S (2013) Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 39:558–568PubMedCrossRef

Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J (2013) Hydroxyethyl starch 130/0.38–0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839PubMedCrossRef

Title: Harm associated with 6 % tetrastarch 130 kDa [hydroxyethyl starch (HES) 130/0.4 and 130/0.42] is robust to sensitivity analysis by excluding Dolecek et al.
Authors: Amit Patel
Umeer Waheed
Stephen J. Brett
Publication date: 01-08-2013
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 8/2013
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-013-2962-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Harm associated with 6 % tetrastarch 130 kDa [hydroxyethyl starch (HES) 130/0.4 and 130/0.42] is robust to sensitivity analysis by excluding Dolecek et al.

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2013

Long-term mortality in patients with chronic obstructive pulmonary disease following extracorporeal membrane oxygenation for cardiac assist after cardiovascular surgery

Research to inform the consent-to-research process

Levosimendan for the treatment of subarachnoid hemorrhage-related cardiogenic shock

Metabolomics in pneumonia and sepsis: an analysis of the GenIMS cohort study

Dyspnea and surface inspiratory electromyograms in mechanically ventilated patients

“Colloid twice daily” is not fluid resuscitation! Inappropriate inclusion of clinical trials in meta-analyses may distract from gaps in evidence